ROS1 Antibody, FITC conjugated
-
中文名稱：ROS1兔多克隆抗體, FITC偶聯
-
貨號：CSB-PA020072LC01HU
-
規格：￥880
-
其他：
產品詳情
-
產品名稱：Rabbit anti-Homo sapiens (Human) ROS1 Polyclonal antibody
-
Uniprot No.：
-
基因名：
-
別名：c ros 1 antibody; c ros antibody; c ros oncogene 1 receptor tyrosine kinase antibody; c Ros receptor tyrosine kinase antibody; c ros1 antibody; MCF 3 antibody; MCF3 antibody; Oncogene ROS antibody; OTTHUMP00000017814 antibody; OTTHUMP00000017815 antibody; OTTHUMP00000040389 antibody; Proto oncogene c ros 1 protein antibody; Proto oncogene c Ros antibody; Proto oncogene tyrosine protein kinase ROS antibody; Proto oncogene tyrosine protein kinase ROS precursor antibody; Proto-oncogene c-Ros-1 antibody; Proto-oncogene tyrosine-protein kinase ROS antibody; Receptor tyrosine kinase c ros oncogene 1 antibody; Ros 1 antibody; ROS 1C antibody; ROS antibody; ROS proto oncogene 1 ; receptor tyrosine kinase antibody; ROS_HUMAN antibody; ROS1 antibody; ROS1C antibody; Transmembrane tyrosine specific protein kinase antibody; v ros avian UR2 sarcoma virus oncogene homolog 1 antibody; v ros UR2 sarcoma virus oncogene homolog 1 antibody
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Recombinant Human Proto-oncogene tyrosine-protein kinase ROS protein (79-248AA)
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：FITC
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 -
產品提供形式：Liquid
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.
-
基因功能參考文獻：
- CEP72-ROS1 is a novel ROS1 fusion variant in non-small cell lung cancer (NSCLC) discovered by next-generation sequencing and could be included in ROS1 detection assay, such as reverse transcription PCR. PMID: 29517860
- The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2. PMID: 30262706
- Although rare, patients with ovarian serous carcinoma or serous borderline tumor may exhibit ROS1 gene rearrangement and ROS1 protein expression PMID: 30249502
- Study based on 47 tissue samples from spitzoid tumors revealed 2 BAP1-inactived cases. The absence of anomalous expression of translocation-related proteins ALK and ROS1 in this series, composed predominantly of low-grade/low-risk tumors, indicates that translocated spitzoid lesions may not be as prevalent as initially suggested, at least in some populations. PMID: 29623743
- None of the genitourinary pseudosarcomatous myofibroblastic proliferations was found to harbour USP6 (0/12), ROS1 (0/8) or ETV6 (0/7) rearrangements PMID: 29617048
- lung adenocarcinoma in Asian patients aged 50 years, especially EML4-ALK and ROS1 fusion. Mutation analysis may be helpful in determining targeted therapy for the majority of these patients PMID: 30107055
- Compared with ROS1-negative advanced NSCLCs,ROS1-rearranged advanced NSCLCs were associated with a younger age at presentation. ROS1 rearrangements were not significantly associated with sex, smoking history, drinking history and metastatic sites. PMID: 27708233
- ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clinical trials using ROS1 inhibitors in these genetically unique patients is warranted. PMID: 27121721
- For intra-hepatic cholangiocarcinomas (IHCC)patients, ROS1, ALK and c-MET expression levels have prognostic significance on clinical outcomes. Although this finding may require further validation, it has led to proposal of a new stratification or enriched biomarker for future phase III trial of anti-EGFR therapy in IHCC PMID: 27136744
- Polymorphisms rs1333049 and rs10757278 are associated with SCD in men and rs499818 in the women aged over 50 years. PMID: 28400043
- Overcome crizotinib resistance in a ROS1-rearranged cancer. PMID: 26673800
- The ROS1 S1986Y/F and ALK C1156Y mutations are homologous and displayed similar sensitivity patterns to ALK/ROS1 TKIs. PMID: 27401242
- Given the results from the ROS1 cohort of the clinical trial PROFILE 1001, crizotinib represents a new treatment option and the first approved therapy for patients with metastatic non-small cell lung cancer whose tumors are ROS1 positive. Crizotinib demonstrated efficacy irrespective of prior treatment status. PMID: 27328934
- ROS1 rearrangements rarely overlap with alterations in EGFR, KRAS, ALK, or other targetable oncogenes in NSCLC. PMID: 28088512
- C-ROS-1 is involved in Bone marrow-derived mesenchymal stem/stromal cell fate switching between osteogenesis and adipogenesis, mediated via PI3K/AKT/mTORC1 signalling. PMID: 27669657
- Findings highlight ROS1 as a candidate biomarker and therapeutic target for oral squamous cell carcinoma. PMID: 28759046
- Studies suggest that the routine clinical use of fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) may be replaced by emerging next-generation sequencing and digital, color-coded barcode technologies, which have the advantage of simultaneously evaluating anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) and epidermal growth factor receptor (EGFR) alterations in a single analysis. PMID: 28743163
- ROS1-positive metastatic lung adenocarcinomas frequently harbor concomitant oncogenic driver mutations. PMID: 27575422
- MFA has a protective effect on alcohol-induced liver injury, which may be related to its antioxidant,anti-inflammatory,lipid-eliminating properties and its ability to regulate the NOX4/ROS-MAPK signalling pathway. PMID: 28890346
- Female, cribriform structure and presence of psammoma body were the three most powerful indicator of ROS1 rearrangement status, and predictive formula was helpful in screening ROS1-rearranged non-small-cell lung carcinomas, especially for ROS1 immunochemistry equivocal cases. PMID: 27648828
- report adds the ZCCHC8-ROS1 fusion as oncogenic driver in GBM and supports the role of ROS1 activation in the pathogenesis of a subset of glioblastoma PMID: 27121553
- ROS1 mutation is associated with response to chemotherapy in lung adenocarcinoma. PMID: 28063177
- A subset of ALK-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism. PMID: 26647767
- High CEP85L-ROS1 expression is associated with neoplasms. PMID: 27153396
- 26 genes were found to fuse with ROS1 and different ROS1 fusions have distinct subcellular localization, suggesting that they may activate different substrates in vivo[review] PMID: 27256160
- ROS1-fusion genes act as a driver for the pathogenesis of lung adenocarcinoma. PMID: 26964870
- High prevalence of ROS1 copy number alterations are frequent in non-small cell lung cancer. PMID: 26783962
- curcumin and ABT-737 on HCC cells was investigated for the first time, to the best of our knowledge. It was found that curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells and activate ROS-ASK1-c-Jun N-terminal kinase pathway . PMID: 26707143
- LIX1L is an RNA-binding protein, with implications for therapeutic approaches for targeting LIX1L in LIX1L-expressing cancer cells. PMID: 26310847
- ADAM9 and ROS1 are direct downstream targets of miR-33a PMID: 26507842
- ALK and ROS1 rearrangements found in advanced non-small cell lung cancer patients PMID: 26152804
- The upregulation of ROS1 and DDR1 was confirmed at the protein level by western blot. Treatment with a potent and specific pyrazole ROS1 inhibitor in ROS1 overexpressing clones led to a sensitization of these cells to low concentrations of gefitinib. PMID: 25978031
- ROS1 protein expression was associated with well-differentiated histology and better survival in our patients with resected intrahepatic cholangiocarcinoma PMID: 26475437
- ROS1 rearrangement was not identified in Glioblastoma Multiforme patients. PMID: 26366867
- ROS1-rearranged adenocarcinoma exhibited distinct morphological and clinicopathological features. PMID: 26149475
- ROS1 gene rearrangment is associated with drug resistance in non-small-cell lung cancer. PMID: 25846554
- ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. PMID: 25868855
- findings suggest that immunohistochemistry for ROS1 may be useful to support the diagnosis of a subset of inflammatory myofibroblastic tumors PMID: 25612511
- Molecular changes associated with acquired crizotinib resistance in ROS1-rearranged non-small cell lung cancer are heterogeneous, including ROS1 tyrosine kinase mutations, EGFR activation, and epithelial-to-mesenchymal transition. PMID: 25688157
- Our findings show good correlation between FISH versus CISH in the detection of ALK and ROS1 rearrangements. FISH versus IHC showed good correlation in the detection of ALK rearrangements PMID: 25789833
- We developed a comprehensive model of acquired resistance to ROS1 inhibitors in non-small cell lung cancer with ROS1 rearrangement and identified cabozantinib as a therapeutic strategy to overcome the resistance. PMID: 25351743
- inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions PMID: 25723109
- Six out of 65 (9%) BTC patients were positive for the FIG-ROS1 fusion, comprising two out of 14 (14%) gallbladder carcinoma (GBC) patients and four out of 25 (16%) extrahepatic cholangiocarcinoma (ECC) patients. PMID: 25231053
- GPX1-dependent alterations in oxido-reductive stress promote ROS1 activation and mediate vascular remodeling. PMID: 25401476
- lung cancer featuring a ROS1 rearrangement may be sensitive to protein kinase inhibitor crizotinib PMID: 25667280
- ROS1 gene copy number gain status is more common in male patients and in cases with squamous histology in non small cell lung cancer PMID: 25374304
- ROS1 translocations are rare events in resected non-small-cell lung cancers from Caucasian patients PMID: 24456475
- EZR-ROS1 fusion gene is associated with response to therapy in metastatic mediastinum lymph node from a non-small cell lung cancer. PMID: 25230898
- Data show that translocations and amplifications of ROS1 gene occur at a similarly low rate in lung cancer brain metastases as reported for primary tumors PMID: 24760415
- None of 268 gliomas analysed showed the FIG-ROS1(L) rearrangement PMID: 24999209
顯示更多
收起更多
-
相關疾病：A chromosomal aberration involving ROS1 is found in a glioblastoma multiforme sample. An intra-chromosomal deletion del(6)(q21q21) is responsible for the formation of GOPC-ROS1 chimeric protein which is localized to the Golgi and has a constitutive receptor tyrosine kinase activity. A SLC34A2-ROS1 chimeric protein produced in non-small cell lung cancer cells also retains a constitutive kinase activity. A third type of chimeric protein CD74-ROS1 was also identified in those cells.
-
亞細胞定位：Cell membrane; Single-pass type I membrane protein.
-
蛋白家族：Protein kinase superfamily, Tyr protein kinase family, Insulin receptor subfamily
-
組織特異性：Expressed in brain. Expression is increased in primary gliomas.
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
-
-
-
-
-
